Sanofi forms new alliance to fight zika in Brazil

pharmafile | October 27, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, Zika 

Sanofi has teamed up with Brazilian research institute Fiocruz to accelerate development of a zika vaccine.

This is another step in Sanofi’s robust plan for development of a vaccine against the mosquito-borne virus. In July, the company formed an alliance with a US Army research institute, and it intends to promote collaboration between this new trio to “increase the likelihood of successfully developing and licensing a safe and effective Zika vaccine as quickly as possible”.

“It only makes sense for the pursuit of public health that we combine our expertise and resources on zika with Fiocruz, which is ideally based in Brazil where the heart of the current zika experience lies,” said John Shiver, senior vice president for research at Sanofi’s vaccines unit.

The French manufacturer also secured $43 million from the BioMedical Advanced Research and Development Authority (BARDA) back in September.

Sanofi has also invested its expertise in other, similar viral areas, developing shots against other so-called flaviviruses, such as yellow fever, dengue and Japanese encephalitis.

Analysts are expecting a vaccine to hit the market in as little as two years.

Related Content

Sanofi announce positive phase 2 data for MS drug frexalimab

French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 …

Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment

Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement …

Sanofi complete acquisition of mRNA company Translate Bio

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal …

Latest content